Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allakos Inc (ALLK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,467,534
  • Shares Outstanding, K 42,113
  • Annual Sales, $ -29,010 K
  • Annual Income, $ 138,750 K
  • 36-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.38
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.55 +10.46%
on 02/12/19
45.56 -23.51%
on 01/28/19
-8.77 (-20.11%)
since 01/15/19
3-Month
31.55 +10.46%
on 02/12/19
65.48 -46.78%
on 12/11/18
-21.07 (-37.68%)
since 11/15/18

Most Recent Stories

More News
Allakos Enters Oversold Territory

Allakos Inc. (ALLK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ALLK : 34.85 (-1.16%)
Allakos to Host Investor Day on February 19 in New York City

Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 starting...

ALLK : 34.85 (-1.16%)
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naive Chronic Spontaneous Urticaria Patients

-- 12 of 13 (92%) patients achieved a complete response --

ALLK : 34.85 (-1.16%)
5 Best-Performing IPOs of 2018

Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.

KNSA : 17.69 (-0.67%)
ALLK : 34.85 (-1.16%)
BJ : 25.86 (+0.04%)
TLRY : 76.49 (-0.17%)
COLD : 28.75 (-0.07%)
EQH : 19.34 (+3.20%)
Allakos (ALLK) Catches Eye: Stock Jumps 6.5%

Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ALLK : 34.85 (-1.16%)
ALXN : 129.42 (+2.77%)
New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TheStreet, Inc. (NASDAQ:TST),...

SORL : 3.21 (-2.73%)
EVOP : 25.67 (+0.35%)
TST : 2.22 (unch)
OMEX : 5.51 (unch)
ALLK : 34.85 (-1.16%)
SGRP : 0.61 (+6.14%)
SGPPY : 14.9200 (unch)
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results

-- Clinical data expected in early first quarter 2019 --

ALLK : 34.85 (-1.16%)
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced the presentation...

ALLK : 34.85 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALLK with:

Business Summary

Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States.

See More

Key Turning Points

2nd Resistance Point 36.57
1st Resistance Point 35.71
Last Price 34.85
1st Support Level 33.98
2nd Support Level 33.11

See More

52-Week High 65.48
Fibonacci 61.8% 50.40
Fibonacci 50% 45.74
Fibonacci 38.2% 41.08
Last Price 34.85
52-Week Low 26.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar